PHARMACOKINETICS IN THE CHILD

被引:52
作者
CROM, WR [1 ]
机构
[1] UNIV TENNESSEE, CTR PEDIAT PHARMACOKINET & THERAPEUT, MEMPHIS, TN USA
关键词
PHARMACOKINETICS; DRUG METABOLISM; BODY SURFACE AREA; LORAZEPAM; INDOCYANINE GREEN; ANTIPYRINE; GROWTH AND DEVELOPMENT; METHOTREXATE; DEBRISOQUIN HYDROXYLASE;
D O I
10.1289/ehp.94102s11111
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Pharmacokinetic studies have made many significant contributions to rational therapeutics in children. Pharmacokinetic data have helped distinguish between differences in drug disposition and drug sensitivity in children as compared to adults and led to the establishment of age-specific dosage guidelines. Factors influencing the observed differences between drug disposition in children and adults are reviewed. Specific examples utilizing anticancer drugs are presented. The use of model substrates to study hepatic drug metabolism and renal excretion in children is described and some results are discussed, The significance of genetic polymorphic drug metabolism is presented and the use of model substrates to determine individual metabolic phenotypes is described. The use of pharmacokinetic data to define the maximum-tolerated systemic exposure rather than the maximum-tolerated dosage oi anticancer drugs in children is presented.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 28 条
[21]  
PETROS WP, 1990, PHARMACOTHERAPY, V10, P31
[22]  
PRANDOTA J, 1987, PEDIATR INFECT DIS J, V6, P1111
[23]   LOWER PREVALENCE OF THE DEBRISOQUIN OXIDATIVE POOR METABOLIZER PHENOTYPE IN AMERICAN BLACK VERSUS WHITE SUBJECTS [J].
RELLING, MV ;
CHERRIE, J ;
SCHELL, MJ ;
PETROS, WP ;
MEYER, WH ;
EVANS, WE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (03) :308-313
[24]  
RELLING MV, 1989, CLIN PHARMACY, V8, P852
[25]  
RELLING MV, 1992, APPLIED PHARMACOKINE
[26]  
RODMAN JH, 1993, PHARMACOTHERAPY, V13, P10
[27]  
VERMEULEN JP, 1986, HEPATOLOGY, V6, P1178
[28]   DRUG CLEARANCE IN PATIENTS WITH CYSTIC-FIBROSIS [J].
WEINBERGER, MM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) :106-106